ISA Pharmaceuticals BV of the Netherlands has appointed Jan Fagerberg, a clinical oncologist and former executive of Amgen Inc, to the position of chief medical officer. ISA is developing therapeutic vaccines against cancer and viral infections. Dr Fagerberg was previously vice president of global development and managing director of Amgen Research (Munich) GmbH. He also has extensive international regulatory experience and was successful in obtaining 11 FDA and EMA approvals for Xeloda (capecitabine) and Avastin (bevacizumab). He received his MD and PhD for work in clinically applied passive and active immunotherapy in cancer from the Karolinska Institutet in Stockholm, Sweden.
Separately, ISA has named Jens Hennecke, a former executive of Micromet Inc (now Amgen), as chief business officer and advisor, and Gerard Platenburg as chief operating officer. Ronald Loggers is stepping down from the board of directors to become acting chief executive.
ISA Pharmaceuticals announced the appointments on 8 July 2013.
Copyright 2013 Evernow Publishing Ltd